SCHEMBL21683014

SCHEMBL21683014

NC1(c2ccncc2)CCCN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.39
EPHX2 P34913 2/20 0.38
CYP2C9 P11712 5/20 0.36
USP2 O75604 4/20 0.36
TSHR P16473 4/20 0.36
CYP2D6 P10635 3/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP3A4 P08684 8/20 0.36
CYP2C19 P33261 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 2/20 0.36
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21683027 0.95 HSD11B1 (0.41) HSD11B1EPHX2CYP2C9USP2TSHR
SCHEMBL3391147 0.85 HSD11B1 (0.44) HSD11B1TSHRMEN1KMT2ALMNA
SCHEMBL3393922 0.81 MEN1 (0.47) HSD11B1TSHRMEN1KMT2ALMNA
SCHEMBL22325834 0.75 HSD11B1 (0.42) HSD11B1CYP2D6MEN1KMT2ASMN1; SMN2
SCHEMBL18285758 0.74 ALDH1A1 (0.33) CYP2C9CYP2C19MEN1KMT2ACYP1A2
SCHEMBL18285754 0.74 ALDH1A1 (0.33) CYP2C9CYP2C19MEN1KMT2ACYP1A2
SCHEMBL28536867 0.71 MEN1 (0.47) HSD11B1TSHRMEN1KMT2ALMNA
SCHEMBL21683080 0.71 HIF1A (0.35) CYP2C9USP2TSHRCYP2D6HSD17B10
SCHEMBL29884115 0.71 GRIN1 (0.48) HSD11B1EPHX2HSD17B10MEN1KMT2A
SCHEMBL18285756 0.70 KDM4E (0.34) HSD11B1CYP2C9CYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3833350-A1 PYRROLOPYRIMIDINE ITK INHIBITORS Aclaris Therapeutics, Inc. (US) 2021-06-16 EP disclosed
WO-2020033955-A1 PYRROLOPYRIMIDINE ITK INHIBITORS ACLARIS THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed